While #ALS patients are forefront in our minds year-round as we work for potential treatments, this month allows the world to come together to honor those living with and lost to ALS, raise awareness and funds, and celebrate the ALS community that is driving toward cures. #ALSAwareness #precisionmedicine #neurodegenerativediseases
QurAlis
Biotechnology
Cambridge, MA 5,883 followers
Neuro Pioneers on a Quest to Cure
About us
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
- Website
-
https://quralis.com/
External link for QurAlis
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- ALS, FTD, ALS Genes, ALS Drug, Precision Therapy, and Precision Medicine
Locations
-
Primary
100 Cambridge Park Drive
5th Floor
Cambridge, MA 02140, US
Employees at QurAlis
Updates
-
QurAlis is honored to sponsor the 2024 ALS Society of Canada Research Forum that was held this past weekend bringing together the brightest minds in Canadian #ALS research to share knowledge and progress toward #aWorldFreeOfALS. #precisionmedicine #neurodegenerativediseases https://bit.ly/4dllqS0
-
Enormous congratulations to Sudhir Agrawal D.Phil, FRSC, member of QurAlis' Scientific Advisory Board, on the peer-review publication of a paper describing his journey in the development of the #ASO platform. The paper entitled, "Considerations for Creating the Next Generation of #RNA Therapeutics: #Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids," appears in the April 2024 issue of Nucleic Acid Therapeutics. https://bit.ly/4d72shT. #precisionmedicine #neurodegenerativediseases
-
QurAlis' CEO and founder Kasper Roet is particpating in the Piper Sandler Spring Biopharma Symposium 2024 being held 4/16-4/17 in Boston. https://bit.ly/3xDYzAV #ALS #FTD #precisionmedicine #neurodegenerativediseases
-
QurAlis at #AAN24! QurAlis' head of development Emma Bowden, PhD, presented a poster on two Phase 1 clinical trials of QRL-101 in #ALS patients. QRL-101 is a first-in-class #Kv7 #precisionmedicine for ALS. #neurodegenerativediseases
-
QurAlis' CEO and founder Kasper Roet recently participated in the The Termeer Foundation International Mission to The Netherlands in what was an exciting collaboration spanning continents, cultures, and disciplines to advance #patientcentered #innovation
-
April 7 is #WorldHealthDay. QurAlis joins millions around the world to help raise awareness about global health issues and champion access to quality health services for all. #healthforall
-
QurAlis is honored to have our CEO and founder Kasper Roet participate in the The Termeer Foundation International Mission to learn about the #biotech and life sciences ecosystem in the Netherlands, and meet and network with industry leaders. The Mission serves as an educational journey, as well as a platform for fostering collaboration, curiosity, and cross-cultural understanding which creates a space for dialogue, shared experiences, and the exchange of ideas. Kasper is pictured here with Ambassador Shefali Razdan Duggal. #precisionmedicine #neurodegenerativediseases
-
QurAlis congratulates the Centre for Animal-Free Biomedical Translation for being awarded a Dutch National Growth Fund grant to accelerate the transition to #animalfree research. QurAlis is proud to partner on this important effort. #precisionmedicine #neurodegenerativediseases
-
Excited to have QurAlis' Global Supply Chain team members (l-to-r: Amit Jain, Patrick Berreby, Guzide (Icke) Adhikari) attend #DCATWeek - the premier global event for companies engaged in the #biopharmaceuticalmanufacturing chain. #ALS #FTD #precisionmedicine #neurodegenerativediseases